http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2058390-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f903fe2baebbfdfae17e80aa4b790a77 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-28 |
| filingDate | 1992-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1996-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0a694bf27c59260e23774658fe981e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c6cc1d5e1a171396a4c5f338382589a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2831cbaaf48f82e55812513b25bb47a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0779e3dd6a291c1d1d8dbd067f33b690 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ff7046090f31be9d7d48864baf28321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_000728600885cf94e5169d524f84f844 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6ec64fa0c546c9854c23fdd7c809ca1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cd4d0bce8830874d2763ad02e5964db |
| publicationDate | 1996-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2058390-C1 |
| titleOfInvention | HYBRID POLYPEPTIDE SHOWING ACTIVITY α1-THYMOSIN-α-TUMOR NECROSIS FACTOR-THYMOSIN a1, METHOD OF PREPARING HYBRID POLYPEPTIDE SHOWING ACTIVITY α1-THYMOSIN-α-TUMOR NECROSIS FACTOR - THYMOSIN a1, RECOMBINANT PLASMID DNA EXPRESSING HYBRID POLYPEPTIDE SHOWING ACTIVITY α1-THYMOSIN α-TUMOR NECROSIS FACTOR - THYMOSIN a1 |
| abstract | FIELD: biotechnology. SUBSTANCE: method involves the construction in vitro of recombinant plasmid DNA containing the gene encoding the synthesis of hybrid protein, - α 1 -thymosin-α-tumor necrosis factor - thymosin-a 1 . Hybrid polypeptide is obtained that shows activity of α 1 -thymosin-α-tumor necrosis factor - thymosin-a 1 (T-TNF-T) and broad spectrum of immuno-modulating action. Also, method involves the construction of plasmid DNA pThy 325 encoding hybrid protein (T-TNF-T), transformant cultivation at 37 C up to the late phase of exponential growth and then to stationary phase at 41 C. For hybrid protein purification the precipitate obtained after cell lysis is used. Precipitate is washed out and dissolved in buffer containing 6M urea. EFFECT: improved method of hybrid protein preparing. 6 cl, 9 dwg, 9 tbl |
| priorityDate | 1992-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.